Abstract: |
There have been major improvements in surgery during the last 150 years in the treatment of genitourinary (GU) oncologic conditions and we're all very aware of its curative nature. Over the past century, great strides have also been made in terms of decreasing mortality rates in patients undergoing surgery, as well as in decreasing morbidity and complications. In the past 15 years, increasing attention has been given to addressing secondary issues such as postoperative pain and the length of hospitalization and recuperation, fostering the development of minimally invasive technologies. Our panel of experts was convened to discuss the past, present, and future role of those technologies and techniques in urologic oncology, This discussion raised concerns about the process whereby new techniques are investigated, marketed, and accepted; how this process challenges urologic dogma; and how it will impact the future of our specialty. |